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Lyme disease, caused by infection with
Borrelia burgdorferi, is the most common tick-
borne disease in the United States and Europe
(1-3). In the United States, the disease has
spread slowly, and the number of cases in
disease-endemic areas has increased (4-6). Most
Lyme disease patients become infected with
B. burgdorferi near their homes, while engaged
in property maintenance, recreation, and
relaxation (7). Occupational and recreational
activities away from home may also pose a risk
(8). Lyme disease prevention based primarily on
avoidance of tick bites, use of repellants, early
detection and removal of attached ticks, and tick
control has not substantially reduced disease
incidence (4-6). Therefore, preventive vaccines
have been of considerable interest. Results of
randomized and blinded phase-III field trials
with recombinant B. burgdorferi outer surface
protein A (rOspA) vaccines indicate that they are
safe and efficacious (9,10). On December 21,
1998, the U.S. Food and Drug Administration
licensed one of the vaccines (LYMErix,
SmithKline Beecham Biologicals, Reixensart,
Belgium) for use in the United States (11).
We present the results of an analytic model
that evaluates the cost effectiveness of using a
vaccine to protect against Lyme disease in the
United States.
The Model
Using a computer-based spreadsheet (Excel
5.0 for Windows, Microsoft), we constructed a
decision tree (12) to evaluate the cost per case
averted (cost effectiveness) to society of
vaccinating against Lyme disease (Figure 1).
Many data needed to determine the cost
effectiveness of vaccinating against Lyme
disease are unvalidated, unavailable, or avail-
able only from very small databases. Thus,
rather than calculate a single estimate of cost per
case averted, we examined the effect of
combinations of six inputs: cost of vaccination;
annual probability of contracting Lyme disease;
costs of successfully treating either early
symptoms of Lyme disease or one of three
sequelae (cardiovascular, neurologic, arthritic);
probability of diagnosing and treating early
symptoms; probability of sequelae due to early
infection; probability of sequelae due to late,
disseminated infection.
Mathematically, we examined the effect of
altering the values of the inputs by using
specialized computer software (@Risk, Palisade
Corp., Newfield, NY) (13) that employs Monte
Carlo methods (14-16). To use these methods, the
researcher defines probability distributions for
selected inputs by using available data and
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diagnosing and treating early Lyme disease, a 0.005 probability of contracting Lyme
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Figure 1: Decision tree to model the cost effectiveness
of vaccinating a person against Lyme disease.
   Cost per        =     $ of vacc+$of LD with vacc-$ of LDw/o vacc
case averted                Prob LD w/o vacc-Prob LD with vacc
enters them into the computer program. For
each iteration of the program, an algorithm
selects input values from the probability
distributions, calculates the net result (here, the
cost per case averted), and stores that result.
After all iterations (typically 1,000 to 5,000) are
completed, the program produces a probability-
based distribution of the net result, which can
then be used to report statistics such as mean,
median, and 5th and 95th percentiles.
Cost Effectiveness Formula
The formula used to calculate the cost per
case of Lyme disease averted was as follows:
where $ = cost; vacc. = vaccination; LD = Lyme
disease; and prob. = probability. The numerator
is the cost of vaccination less any savings
resulting from the reduced probability of
contracting the disease (decreased incidence)
due to vaccination. If the vaccine is not 100%
effective in preventing Lyme disease (i.e., if the
term Prob. LD with vacc. >0), treatment costs
may still be incurred after vaccination. The cost
of a case of Lyme disease is the weighted average
cost of all health outcomes (Figure 1), where the
weights are the probabilities of those outcomes
(12). The denominator reflects the change in the
probability of Lyme disease due to vaccination.
Vaccine Timeline
Although experiments have shown that a
Lyme disease vaccine using rOspA is safe and
immunogenic in both animals and humans (17-
23), no data have been published concerning the
decrease in antibody levels over more than 20
months (9). Phase-III vaccine field trials used a
0-, 1-, and 12-month immunization schedule, and
antibody levels dropped almost 10-fold between
the month after the second dose and just before
the third dose at month 12 (9). The third dose at
month 12 boosted antibodies to levels higher
than measured at month 2, but these declined by
half by month 20 (9). We assumed, therefore,
that an annual booster dose would be required
and that the cost-effectiveness model would be
repeated annually. When calculating annual
benefits, however, we included the discounted
savings of preventing Lyme disease that may
generate multiyear sequelae.
Lyme Disease Symptoms and Sequelae
The most common symptoms of infection
with  B. burgdorferi can be categorized as early
localized disease (stage I); early disseminated
disease (stage II); and later-stage sequelae of
disseminated infection (stage III) (24). Stages I
and II correspond to the branches labeled
Recognize early LD? Yes in Figure 1, and stage
III corresponds to the branches labeled
Recognize early LD? No. Most early symptoms
of Lyme disease respond promptly and com-
pletely to short courses of oral antibiotics (25-27).
Later-stage sequelae, however, may require
costly, more prolonged treatment, sometimes
repeated courses of treatment using intravenous
cephalosporins, and may not be completely
eliminated (28).
If a person, vaccinated or unvaccinated,
contracts Lyme disease, the model allows for one
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(29-31): cardiovascular sequelae (e.g., high-
grade atrioventricular blocks); neurologic se-
quelae (e.g., isolated cranial nerve palsy,
meningitis); arthritic or rheumatologic/muscu-
loskeletal sequelae (e.g., episodic oligoarticular
arthritis, arthralgia); and case resolved (after a
course of an oral antibiotic such as doxycycline)
with no further complications.
The disseminated stages of Lyme disease
may be manifested weeks to months after
infection (24). However, few data concerning the
duration of such sequelae are available. One
study, for example, involving 38 patients showed
that their long-term clinical sequelae lasted a
mean of 6.2 years from onset of disease (32). The
use of health-care resources, however, by those
patients during that time was not reported. We
assumed that cardiovascular sequelae would be
treated and resolved in an average of 1 year and
that late neurologic and arthritic sequelae would
both take an average of 11 years to diagnose and
satisfactorily treat to full resolution (initial year
of diagnosis and treatment plus 10 years of
additional treatment). These assignments of
average time are arbitrary and longer than any
published average, which maximizes estimated
economic benefits of using a vaccine.
Probabilities
We selected three probabilities (0.005, 0.01,
and 0.03) of contracting Lyme disease (Table 1)
on the basis of data concerning disease incidence
in Lyme disease-endemic areas (33-36); the
probability of 0.03 is among the highest reported.
(Before the risk for Lyme disease was widely
recognized, a one-time annual incidence of 10%
was reported in a community of 190 people living
next to an open nature preserve [37].) Vaccine
efficacy in preventing Lyme disease was 50%
(95% confidence intervals [CI]: 14% to 71%) after
the first two doses and 78% (95% CI: 59% to 88%)
after three doses (9,11). We assumed Lyme
disease vaccine to be 85% effective, which is near
the upper end of the 95% confidence limits and
thus maximizes estimated economic benefits. We
selected 0.6 to 0.9 as the range of probability of
early diagnosis and treatment on the basis of a
study on the economic cost of Lyme disease,
which included data from an expert panel (38).
For the Monte Carlo simulations (14-16), we
constructed the distributions describing the
probabilities of having one of the three sequelae
(due to either early or late disseminated disease)
using data from the previously mentioned expert
panel (Table 1) (38). The distributions describing
cardiac and neurologic complications associated
with early Lyme disease are uniform, defined by
using minimum and maximum values (39) and
reflecting the uncertainty regarding a most
likely value (38). All other distributions are
triangular (39), with minimum, most likely, and
maximum values (Table 1).
Table 1. Probabilities and their statistical distributions
Item Values Type of distributiona
Probability of contracting LDb 0.005, 0.01, 0.03 Fixed intervalsc
Effectiveness of vaccine 0.85 Fixed
Probability of early detection of LD 0.6 - 0.9 Fixed intervalscd
Probability of sequelaee if detect LD early
              Cardiac 0 - 0.01 Uniformf
              Neurologic 0 - 0.02 Uniformf
              Arthritic 0.02-0.05-0.07 Triangularg
              Case resolved Residualh N/A
Probability of sequelae if do not detect LD early
              Cardiac 0.02-0.03-0.06 Triangular
              Neurologic 0.02-0.15-0.17 Triangular
              Arthritic 0.5-0.6-0.62 Triangular
              Case resolved Residualh N/A
aStatistical distribution used in Monte Carlo simulations (14-16).
bLD = Lyme disease.
cIterations are run by using different combinations of the probabilities of infection and cost of treatment (Table 2).
dThe interval between the minimum and the maximum is divided into 0.1 increments.
eSee text for description of sequelae.
fUniform distribution implies that there is an equal chance that any number between, and including, the minimum and
maximum will be used for a given iteration.
gTriangular distribution is defined by points of minimum, most likely, and maximum.
hThe probability of an LD case being successfully resolved (i.e., no further sequelae) is 1 - (sum of  the probabilities of cardiac +
neurologic + arthritic symptoms).324 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Table 2: Costs of treating one case of Lyme disease and
the sequelae due to early and late disseminated disease
Cost/ Length Total
year of treat- costsa
Item  ($) ment ($)
Case resolved: no sequelae
Antibiotics     14
Office visits (2)     50
Laboratory tests     35
5 hrs lost work time     62
      Total    161 2-3 wks      161
Sequelaeb due to early and
  late disseminated disease
Cardiac-directc 5,445
Cardiac-indirectd 1,400
Cardiac-total 6,845 £ 1 yr   6,845
Neurologic-directc 4,865
Neurologic-indirectd 2,100
Neurologic-total 6,965 11 yrs 61,243
Arthritic-directc 1,804
Arthritic-indirectd 2,100
Arthritic-total 3,904 11 yrs 34,354
aAll costs that occur over more than 1 year are discounted at
a rate of 3% per year.
bSee text for description of the sequelae.
cDirect costs are for all medical costs and are derived from the
1-year charges reported by Magid et al. (29), inflated to 1996
dollars (factor of 1.528) (40), and then adjusted by a cost-to-
charge ratio of 0.53 (43) (see text for details).
dIndirect costs are the valuation of lost productivity due to
Lyme disease-related illness, with each day lost valued at
$100. For cardiac-related sequelae, it was assumed that 14
workdays were lost, and for neurologic and arthritic-related
sequelae, it was assumed that 21 workdays were lost each year.
Vaccination Costs
Although a Lyme disease vaccine has been
licensed (11), data are not available on the actual
cost of vaccination, which includes costs of the
vaccine, its administration, time spent in
receiving the vaccine, travel, and treatment of
adverse side-effects of vaccination. To allow for
variation caused by variables such as location of
provider, type of provider, and type of third-
party payer, we estimated cost effectiveness by
using three costs: $50 per person per year, $100 per
person per year, and $200 per person per year.
Few data are available on the costs of
treating a case of Lyme disease; only one study
(29) has documented the charges in 1989 dollars
associated with some sequelae. To adjust charges
reported in that study to 1996 prices, we
multiplied the charges by a factor of 1.528
(medical care component of the consumer price
index) (40). These 1996 prices, however,
reflected health-care charges paid by health
insurance companies and not necessarily actual
economic costs (41,42). Thus, to reflect economic
costs, the adjusted prices were multiplied by
cost-to-charge factor (the weighted average of
the urban and rural hospital cost-to-charge
ratios used by the U.S. Federal Health Care
Finance Administration [43]) of 0.53. Data
describing indirect costs, particularly lost
productivity, associated with sequelae were
unavailable. We therefore assumed that Lyme
diseaserelated cardiac sequelae would cause 14
days of lost productivity, and neurologic and
arthritic sequelae would each cause 21 days of
lost productivity per year. Each day of lost
productivity was valued at $100 (the average
income of a workday [1990 dollars inflated to
1996 values] weighted by the age and sex
composition of the U.S. workforce) (44). Because
we assumed that late-stage neurologic and
arthritic complications may take up to 11 years
to completely resolve, the 1-year cost estimates
for treating these sequelae were replicated over
11 years and then discounted at 3% to the base
year (Table 2).
We also altered the estimate of Magid et al.
(29) of charges for resolving a case of Lyme
disease without complications by doubling the
number of office visits to two ($25 each visit) and
allowing for 5 hours of lost productivity ($62) for
a total of $161 (Table 2). In comparison, a recent
study concerning Lyme disease on the eastern
shore of Maryland found the median charge for
the diagnosis and treatment of Lyme disease was
$199 (45); this figure represents charges, and
actual economic costs are likely lower than this
amount (41,42).
Sensitivity Analyses
To allow for uncertainty caused by lack of
data, we conducted multivariate sensitivity
analyses in which we simultaneously altered the
assumed effectiveness of the vaccine and the cost
of treating sequelae. We altered vaccine
effectiveness to either 0.75 or 0.95 (compared
with 0.85 in the base case [Table 1]), and we
multiplied the total costs for treating sequelae
(Table 2) by 0.5 or 1.5. For example, for
neurologic sequelae, the latter multiplier is
equivalent to increasing the days of lost
productivity (indirect costs) from 21 days per
year to 31.5 days per year. We set the probability
of identifying and successfully treating early
Lyme disease at 0.80 and the cost of vaccination325 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Figure 2: Average cost effectiveness of vaccinating a person against Lyme disease with changes in the cost of
vaccination, probabilities of identifying and treating early Lyme disease, and probabilities of contracting Lyme
disease. A negative value indicates that vaccinating a person will result in a net cost to society, while a positive value
indicates a net savings to society. The results shown are the means from Monte Carlo simulations (see Table 1 and
text for further details). Vaccine assumed 85% effective (Table 1).
at $100 per year. The estimates generated by
these sensitivity analyses were compared with
those generated using the base costs, with an
assumed vaccine effectiveness of 0.85, and with
the same assumptions for probability of identifying
and treating early Lyme disease and cost of
vaccination as used in the sensitivity analyses.
Findings
Assuming a 0.005 probability of contracting
Lyme disease, a 0.80 probability of diagnosing
and treating early Lyme disease, and a $50 per
year cost of vaccination, the mean cost per case
averted was $4,466 (5th percentile = $5,408; 95th
percentile = $3,587) (Figure 2). The 5th and 95th
percentiles were calculated as part of the Monte
Carlo simulations (14-16). To enhance clarity,
the 5th and 95th percentiles were not plotted on
Figure 2. Increasing the cost of vaccination to
$100 per year increased the mean cost per case
averted to $16,231 (5th = $17,267; 95th =
$15,298) (Figure 2). At a cost of vaccination of $200
per year, the mean cost per case averted was
$39,761 (5th = $40,858; 95th = $38,830) (Figure 2).
With a 0.01 probability of contracting Lyme
disease and a 0.80 probability of correct
diagnosis and treatment of early disease, the
mean savings per case averted was $1,416 when
the cost of vaccination was $50 per year.
Vaccination resulted in a net cost of $4,467 when
the cost of vaccination was $100 per year and a
net cost of $16,231 when the cost of vaccination
was set at $200 per year (Figure 2).
When we set the probability of contracting
Lyme disease at 0.03 and used the same
probability of diagnosis as before (0.80), the mean
savings per case averted was $5,337 when the cost
of vaccination was $50 per year and $3,377 when
the cost of vaccination was $100 per year. The net
cost per case averted was $545 when the cost of
vaccination was $200 per year (Figure 2).
When the costs of treating sequelae were
reduced by half of base costs, at a 0.01 probability
of contracting Lyme disease, the average cost of
averting one case was $9,684 when vaccine
effectiveness was assumed to be 0.75 and $6,877
when vaccine effectiveness was assumed to be
0.95 (Table 3). These are 117% and 54% higher,
respectively, than the costs calculated using the
base costs (Table 3).
When the costs of treating sequelae were
increased to 1.5 times base costs, the equivalent326 Emerging Infectious Diseases Vol. 5, No. 3, MayJune 1999
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Table 3.  Sensitivity analyses: Cost or savings per case averted (5th, 95th percentiles) by altering assumed vaccine
effectiveness and the cost of treating Lyme disease sequelaea
Probability Base treatment costsb x 0.5 Base treatment costsc Base treatment costsb x 1.5
of Lyme Vaccine effectivenessd Vaccine effectivenessd
disease 0.75 0.95 0.85 0.75 0.95
0.005 23,018 17,404 16,231 15,720 10,105
(23,527; 22,556) (17,947; 16,927) (17,283; 15,261) (17,249;14,286) (11,641;8,703)
0.01   9,684   6,877   4,467   2,386 Net savingse
  (10,178; 9197)    (7,372; 6,412)     (5,531; 3,487)      (3,846; 958)  (1,220; savee)
0.03      795  Net savingse   Net savingse  Net savingse Net savingse
      (1,303; 330)       (385; savee)      (save; savee)      (save;savee)   (save; savee)
aThese results were generated by setting the probability of detecting and successfully treating early Lyme disease at 0.80 and
the cost of vaccination at $100 per year.
bBase treatment costs are given in Table 2. The data presented in this table were generated by multiplying the costs in Table 2
by either 0.5 (i.e., reducing costs by half) or by 1.5 (i.e., increasing costs by half).
cFor comparison, the results using the base costs (Table 2) are presented here, assuming a vaccine effectiveness of 0.85. Figure
2 presents the complete set of results using the base costs.
 dThe initial assumed level of vaccine effectiveness was 0.85 (Figure 2).
eNet savings are generated when a person is vaccinated against Lyme disease and the costs saved by not having to treat a case
of Lyme disease are higher than the costs of vaccination plus the costs of having to treat a case of Lyme disease that occurs after
vaccination. The net savings range from $140 (probability of Lyme disease = 0.03, vaccine effectiveness = 0.95, cost of treating
Lyme disease sequelae = 0.5 x  base costs) to $7,438 (probability of Lyme disease = 0.03, vaccine effectiveness = 0.95, cost of
treating Lyme disease sequelae =1.5 x  base costs). Note also that in some instances where mean net savings are calculated, the
5th percentiles are net costs.
cost per case averted was $2,386 at a vaccine
effectiveness of 0.75, while a vaccine effective-
ness of 0.95 was estimated to generate cost
savings (Table 3). The former estimate
represents a 47% decrease in cost per case
averted compared with the base case (Table 3).
These results show that, as the weighted
average cost of treating a case of Lyme disease
decreases (increases), the cost per case averted
through vaccination increases (decreases). An
inspection of the formula to calculate the cost per
case of Lyme disease averted, presented in the
Model section, shows that, as the term $ of LD
w/out vacc (in the numerator) decreases, the cost
per case averted must increase.
Conclusions
Because of either lack of data or wide
variability in some key variables (e.g., cost of
vaccination, risk for Lyme disease), a single
answer regarding the cost effectiveness of
vaccinating a person against Lyme disease
cannot be calculated. The methods we used allow
physicians, health-care decision makers, and
public health authorities to use Figure 2 and
Table 3 to determine the cost effectiveness of
vaccination for their specific situations. This
simple model can be rerun to provide estimates
per case averted for situations not covered in the
results presented (e.g., lower or higher
probabilities of Lyme disease). The estimates do
not include any valuation of a persons
willingness to pay for the vaccination.
Relative Importance of Input Variables
The probability of contracting Lyme disease
is the most important factor in determining the
economic benefit of vaccinating against Lyme
disease (Figure 2). The results from Figure 2 and
from the sensitivity analyses concerning the
costs of treating sequelae and vaccine effective-
ness (Table 3) indicate that the next most
important variables are the cost of treating
sequelae and the probability of early detection
and treatment of Lyme disease.
Research Priorities
Given the importance of treatment costs in
assessing the cost effectiveness of Lyme disease
vaccine, accurate data regarding the cost of
treating sequelae should receive high priority
when setting a research agenda for Lyme
disease. Data concerning the duration of the
various forms of long-term sequelae and the
indirect costs borne by patients are also
important. For both items, research should not
focus on obtaining a mean value but rather on
collecting sufficient data to describe the
probability distribution of these input variables,
which could either replace the assumed
distributions (Table 1) or be added to the model to
further refine the results.327 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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Implications for Public Health Policy
Very few communities have an annual
incidence of Lyme disease of 0.005 or higher.
From 1992 to 1996, approximately 47% (1,483) of
U.S. counties reported at least one case of Lyme
disease. However, 148 counties (almost all in the
northeastern and northcentral United States
[CDC, unpub. data; 1]) reported 90.3% of cases.
Connecticut and Rhode Island had the highest
cumulative annual incidences of reported Lyme
disease, equivalent to probabilities of contracting
Lyme disease of 0.000949 and 0.000539,
respectively (1996 data) (46). Two studies (47,48)
have shown that cases have been underreported
in areas where the disease is highly endemic.
However, the range of probabilities in our model
allows for both underreporting and overdiagnosis.
The benefits are likely highest if both
community-level incidence of Lyme disease and
individual risk for exposure to tick bites and
infection (38) can be considered in using the
vaccine. The Advisory Committee on Immuniza-
tion Practices, Public Health Service, U.S.
Department of Health and Human Services,
recently agreed with this conclusion and voted,
in February 1999, to recommend the use of Lyme
disease vaccine on the basis of a combination of
both community-level and individual risk. These
recommendations will be published soon (49).
Ours is not the only study to suggest that the
vaccine not be used universally. A forthcoming
Institute of Medicine report (50) uses cost per
quality-adjusted life year (QALY) saved to
examine vaccine priorities. The authors estimate
that it would cost more than $100,000 per QALY
saved if the vaccine were given . . . to resident
infants born in, and immigrants of any age to,
geographically defined high risk areas. This
result led the authors to rank Lyme disease
vaccine as less favorable, their lowest ranking
in terms of priorities for vaccine development.
Our model also considers the relative value
of two interventions: vaccination and the detection
and treatment of early Lyme disease. Communi-
ties with average individual probabilities of
contracting Lyme disease of less than 0.01 may
benefit from interventions that improve the
probability of early diagnosis and treatment of
Lyme disease.
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